PCP
UTHR icon

Perbak Capital Partners’s United Therapeutics UTHR Stock Holding History

Perbak Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$853K Buy
+1,438
New +$716K 0.21% 97
2025
Q4 		– Sell
-1,903
Closed -$798K – 320
2025
Q3 		$798K Buy
1,903
+1,180
+163% +$397K 0.14% 163
2025
Q2 		$208K Buy
+723
New +$216K 0.05% 271

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Perbak Capital Partners's UTHR Position: Q1 2026 in Review

Perbak Capital Partners opened a new position in United Therapeutics (UTHR) in Q1 2026: 1,438 shares worth $853K. The stake represents 0.21% of the portfolio and ranks #97 among its holdings. This is a return to the name: Perbak Capital Partners previously reported a position in UTHR as recently as Q3 2025.

Perbak Capital Partners first reported a position in UTHR in Q2 2025 and has held it in 3 quarters since. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Perbak Capital Partners held 1,438 shares of United Therapeutics worth $853K as of Q1 2026.
  • United Therapeutics was a new Perbak Capital Partners position in Q1 2026.
  • United Therapeutics made up 0.21% of Perbak Capital Partners's portfolio in Q1 2026, its #97 holding.
  • Perbak Capital Partners first reported a position in United Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.